$-0.01 EPS Expected for Antibe Therapeutics (ATE); Apogee Enterprises Has 1.3 Sentiment

November 14, 2017 - By Hazel Jackson

Apogee Enterprises, Inc. is engaged in the design and development of glass solutions for enclosing commercial buildings and framing art. The company has market cap of $1.33 billion. The Firm operates through four divisions: Architectural Glass, Architectural Services, Architectural Framing Systems and Large-Scale Optical Technologies . It has a 16.93 P/E ratio. The Architectural Glass segment fabricates coated glass used in customized window and wall systems.

Analysts expect Antibe Therapeutics Inc (CVE:ATE) to report $-0.01 EPS on December, 5.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.01 EPS. After having $-0.02 EPS previously, Antibe Therapeutics Inc’s analysts see -50.00% EPS growth. It closed at $0.09 lastly. It is down 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock decreased 0.56% or $0.26 during the last trading session, reaching $46.43. About shares traded. Apogee Enterprises Inc (APOG) has risen 21.13% since November 14, 2016 and is uptrending. It has outperformed by 4.43% the S&P500.

Sg Capital Management Llc holds 6.79% of its portfolio in Apogee Enterprises Inc for 672,744 shares. Zpr Investment Management owns 61,375 shares or 5.34% of their US portfolio. Moreover, Neumeier Poma Investment Counsel Llc has 2.87% invested in the company for 433,600 shares. The California-based Falcon Point Capital Llc has invested 2.75% in the stock. Copper Rock Capital Partners Llc, a Massachusetts-based fund reported 658,289 shares.

Analysts await Apogee Enterprises Inc (NASDAQ:APOG) to report earnings on December, 13. They expect $1.04 earnings per share, up 33.33% or $0.26 from last year’s $0.78 per share. APOG’s profit will be $29.79 million for 11.16 P/E if the $1.04 EPS becomes a reality. After $0.75 actual earnings per share reported by Apogee Enterprises Inc for the previous quarter, Wall Street now forecasts 38.67% EPS growth.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The company has market cap of $14.67 million. The Firm is focused on pain, inflammation and regenerative medicine. It currently has negative earnings. The Company’s divisions include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com